Becton, Dickinson and Company

Company Overview

Business Model: Becton, Dickinson and Company is a global medical technology company focused on the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. These offerings serve healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company's solutions aim to improve medication management and patient safety, support infection prevention, equip surgical and interventional procedures, enhance drug delivery and anesthesiology care, improve infectious disease and cancer diagnosis, and advance cellular research.

Market Position: Becton, Dickinson and Company operates in a complex and competitive medical technology market characterized by rapid technological advancements, evolving scientific discoveries, and a rigorous regulatory environment. Competition stems from large medical device companies, specialized firms, new entrants in molecular diagnostics, point-of-care testing, safety-engineered devices, and life sciences, as well as traditional distributors expanding into manufacturing. The company competes on factors including price, quality, innovation, service, reputation, distribution, and promotion. Becton, Dickinson and Company states its associates' diverse expertise has helped it achieve a leading position in the medical technology industry and global marketplace.

Recent Strategic Developments:

• Acquisition: On September 3, 2024, Becton, Dickinson and Company acquired Edwards Lifesciences’ Critical Care product group, subsequently renamed BD Advanced Patient Monitoring, for $3.914 billion. This acquisition expanded the company's portfolio of smart connected care solutions.
• Proposed Combination: On July 13, 2025, Becton, Dickinson and Company entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction. Becton, Dickinson and Company shareholders are expected to own approximately 39.2% of the combined entity, and Becton, Dickinson and Company anticipates receiving a cash distribution of approximately $4 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026.
• Divestiture: In August 2023, Becton, Dickinson and Company completed the sale of the Interventional segment’s Surgical Instrumentation platform, recognizing a pre-tax gain of approximately $268 million.
• Organizational Reorganization: Effective October 1, 2025, Becton, Dickinson and Company reorganized its operational units into five distinct segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences (the latter remaining until the Biosciences and Diagnostic Solutions business combination with Waters Corporation is completed).
• Innovation & Product Launches: The company received 510(k) clearance from the FDA for its updated BD Alaris Infusion System on July 21, 2023, and again on April 25, 2025, enabling remediation and a return to market for the system. The Biosciences unit also launched the BD FACSDiscover A8 Cell Analyzer.
• Strategic Pillars: Becton, Dickinson and Company's strategy is anchored in three pillars: "Grow" (accelerating innovation in smart devices, robotics, analytics, AI; focusing on core products; R&D investment; global scale; strategic acquisitions; cash management), "Simplify" (driving operating effectiveness and margin expansion via BD Excellence program; reducing complexity; investing in quality management; digitalization; supply chain collaboration; renewable energy), and "Empower" (fostering a purpose-driven, inclusive culture; talent development; sustainability initiatives).

Geographic Footprint: Becton, Dickinson and Company manufactures and sells its products worldwide. Its international operations are organized across EMEA (Europe, Middle East, and Africa), Greater Asia (Greater China, Japan, South Asia, Southeast Asia, Korea, Australia, and New Zealand), Latin America (Mexico, Central America, the Caribbean, and South America), and Canada. Manufacturing facilities are located in 16 countries outside the United States, including Bosnia and Herzegovina, Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, Switzerland, and the United Kingdom. Research and development activities are conducted at global centers of excellence in the United States, India, China, Singapore, and Ireland, with the majority in North America.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 45.4%
• Operating Margin: 11.8%
• Net Margin: 7.7%

Investment in Growth:

• R&D Expenditure: $1.265 billion (5.8% of revenue)
• Capital Expenditures: $760 million
• Strategic Investments: The acquisition of Advanced Patient Monitoring for $3.914 billion in fiscal year 2024.

Business Segment Analysis

BD Medical

Financial Performance:

• Revenue: $11.456 billion (+13.7% YoY)
• Operating Margin: 36.1%
• Key Growth Drivers: Volume growth in the Medication Delivery Solutions unit's Vascular Access Management portfolio and hypodermic products, partially offset by volume-based procurement (VoBP) impact in China. Growth in the Medication Management Solutions unit was driven by infusion systems, partially offset by the timing of dispensing and pharmacy automation installations. The Pharmaceutical Systems unit saw high single-digit growth in prefillable solutions for biologic drugs, partially offset by lower market demand in other categories. Overall segment growth was significantly boosted by sales from the Advanced Patient Monitoring unit, acquired in the fourth quarter of fiscal year 2024.
• Operating income as a percentage of revenues increased due to lower manufacturing costs from continuous improvement, supply chain optimization, and productivity initiatives, coupled with a favorable product mix from Advanced Patient Monitoring products. This was partially offset by tariffs and higher labor costs.

Product Portfolio:

• Medication Delivery Solutions: Peripheral intravenous (IV) catheters, safety-engineered IV catheters, IV sets, connectors, preparation and accessories, hypodermic syringes and needles.
• Medication Management Solutions: IV medication safety and infusion therapy delivery systems, pharmacy and dispensing automation systems, medication and supply management solutions.
• Pharmaceutical Systems: Prefillable drug delivery systems, including prefillable syringes, self-injection systems, and needle technologies.
• Advanced Patient Monitoring: Advanced hemodynamic monitoring systems used to measure heart function and fluid status.

Market Dynamics: The segment experienced an expected VoBP impact in China for Medication Delivery Solutions and timing-related offsets in Medication Management Solutions due to customer readiness for installations.

BD Life Sciences

Financial Performance:

• Revenue: $5.167 billion (-0.5% YoY)
• Operating Margin: 31.8%
• Key Growth Drivers: Growth in the Specimen Management unit's BD Vacutainer portfolio was partially offset by a decline in China. The Diagnostic Solutions unit experienced a decline due to lower sales of BD BACTEC blood culture products (following resolution of a supply disruption) and point-of-care products, partially offset by double-digit growth in BD MAX IVD. The Biosciences unit saw a decline from market dynamics impacting instruments and reduced life science research funding in the United States and China, partially offset by strong sales of the recently launched BD FACSDiscover A8 Cell Analyzer.
• Operating income as a percentage of revenues increased, primarily reflecting lower manufacturing costs from continuous improvement projects, supply chain optimization, and productivity initiatives, partially offset by higher labor costs, tariffs, and unfavorable foreign currency translation.

Product Portfolio:

• Specimen Management: Blood collection systems, including safety-engineered blood collection sets, needles, holders, and tubes.
• Diagnostic Solutions: Automated blood culturing and tuberculosis culturing systems, molecular diagnostics, rapid diagnostic assays, microbiology laboratory automation, and plated media.
• Biosciences: Fluorescence-activated cell sorters and analyzers, reagents, antibodies, kits, software, and services.

Market Dynamics: The segment faced declines in China for Specimen Management and reduced life science research funding in the United States and China impacting Biosciences.

BD Interventional

Financial Performance:

• Revenue: $5.217 billion (+4.8% YoY)
• Operating Margin: 43.2%
• Key Growth Drivers: Strong growth in the Surgery unit's advanced tissue regeneration portfolio, biosurgery, and infection prevention products, partially offset by lower U.S. revenues from legacy hernia products. The Peripheral Intervention unit saw strong growth in its peripheral vascular disease portfolio, particularly from the Rotarex Atherectomy System, partially offset by a VoBP impact in China. The Urology and Critical Care unit continued to achieve double-digit growth in its PureWick offerings.
• Operating income as a percentage of revenues increased, primarily reflecting lower manufacturing costs from continuous improvement projects, supply chain optimization, and productivity initiatives, partially offset by tariffs, higher labor, and raw material costs.

Product Portfolio:

• Surgery: Hernia and soft tissue repair, biological grafts, hemostatic products, laparoscopic instruments, and infection prevention products.
• Peripheral Intervention: Percutaneous transluminal angioplasty (PTA) balloons, stents, atherectomy devices, drug-coated balloons, embolics, biopsy devices, drainage catheters, ports, and vascular access management products.
• Urology and Critical Care: Urine management and measurement devices, indwelling catheters, continence products, temperature management systems, and endourological instruments.

Market Dynamics: The segment experienced lower U.S. revenues from legacy hernia products in Surgery and a VoBP impact in China for Peripheral Intervention.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Becton, Dickinson and Company repurchased $1.000 billion of its common stock (4.533 million shares) in fiscal year 2025. The company has two authorized repurchase programs, totaling approximately 12 million shares remaining unused as of September 30, 2025. An additional $250 million in open market repurchases occurred in November 2025.
• Dividend Payments: Becton, Dickinson and Company paid $1.196 billion in cash dividends to common shareholders in fiscal year 2025.
• Future Capital Return Commitments: The company has authorized share repurchase programs with no expiration date.

Balance Sheet Position:

• Cash and Equivalents: $641 million (excluding restricted cash). Total cash and equivalents and short-term investments, including restricted cash, were $859 million.
• Total Debt: $19.181 billion
• Net Cash Position: -$18.322 billion
• Credit Rating:
  • Standard & Poor's Ratings Services: BBB (Stable Outlook)
  • Moody's Investors Service: Baa2 (Stable Outlook)
  • Fitch Ratings: BBB (Stable Outlook)
• Debt Maturity Profile: Aggregate annual maturities of long-term debt (including interest) are $2.228 billion in 2026, $3.163 billion in 2027, $2.486 billion in 2028, $2.629 billion in 2029, and $1.144 billion in 2030.

Cash Flow Generation:

• Operating Cash Flow: $3.430 billion (from continuing operating activities)
• Free Cash Flow: $2.670 billion (Operating Cash Flow less Capital Expenditures)

Operational Excellence

Production & Service Model: Becton, Dickinson and Company's production model involves global manufacturing and distribution. The company operates consolidated distribution facilities worldwide to enhance customer service, optimize logistics, reduce facility costs, and manage finished goods inventory. Becton, Dickinson and Company maintains quality systems aligned with International Organization for Standardization standards and FDA regulations for product design, manufacturing, and distribution. Its facilities are generally in good physical condition, suitable for operations, fully utilized, and operating at normal capacity.

Supply Chain Architecture: Key Suppliers & Partners: Becton, Dickinson and Company procures a diverse range of raw materials and components, including plastics, glass, metals, textiles, paper products, agricultural products, electronic and mechanical sub-assemblies, and various biological, chemical, and petrochemical products. The company relies on sole suppliers for certain proprietary or patented materials and components, with rigorous qualification processes (3-18 months, or 1-3 years if clinical trials are required) for alternate sources. Sterilization services are provided by both internal facilities and third parties, with ethylene oxide being the most frequently used sterilant. Facility Network:

• Manufacturing: Becton, Dickinson and Company owns or leases 290 facilities globally, totaling approximately 26 million square feet, for manufacturing, warehousing, administrative, and research purposes. Manufacturing operations are conducted in the United States and 16 other countries.
• Research & Development: R&D activities are conducted at operating units and global centers of excellence located in the United States, India, China, Singapore, and Ireland, with the majority in North America. The company also collaborates with universities, medical centers, and other entities on R&D programs.
• Distribution: Becton, Dickinson and Company utilizes consolidated distribution facilities worldwide.

Operational Metrics: The company reports lower manufacturing costs resulting from continuous improvement projects, supply chain optimization, and other productivity initiatives across its segments. Facilities are generally fully utilized and operating at normal capacity.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: Becton, Dickinson and Company markets and distributes its products through independent distribution channels and directly to end-users via its own sales representatives. In the United States, acute care, non-acute care, laboratory, and drug wholesaler distributors support disposable product demand, while capital equipment is primarily sold direct. International distribution varies by country, utilizing both direct sales and distributors. Digital Platforms: The company is enhancing customer experiences through the digitalization of internal processes and go-to-market approaches.

Customer Portfolio: Becton, Dickinson and Company serves a broad customer base including hospitals, clinics, physicians’ office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, healthcare workers, laboratories, blood banks, academic and government institutions, biotechnology companies, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients through its Homecare business. Customer Concentration: No single customer accounted for 10% or more of total revenues in any of the three years presented.

Geographic Revenue Distribution:

• United States: $12.790 billion (58.6% of total revenue)
• International: $9.049 billion (41.4% of total revenue)
  • EMEA: $4.729 billion
  • Greater Asia: $3.093 billion
  • Other (Latin America & Canada): $1.227 billion
• Growth Markets: Emerging markets (Eastern Europe, Middle East, Africa, Latin America, and certain countries within Greater Asia) generated $3.133 billion in revenue, reflecting a 3.8% year-over-year increase on a foreign currency-neutral basis.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical technology industry is characterized by increasing complexity, rapid technological change, and a more rigorous regulatory environment. Economic conditions have created a challenging market, with significant industry consolidation leading to larger competitors and greater purchasing power among consolidating healthcare systems and providers. A global trend towards limiting healthcare costs, including value-based payment reforms and competitive bidding programs (e.g., CMS Competitive Bidding Program, China's VoBP), is intensifying pricing pressure.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Becton, Dickinson and Company faces competition from large medical device companies with extensive product lines, specialized firms targeting specific markets, non-traditional technology companies entering healthcare, and traditional distributors that have become medical device manufacturers. Emerging Competitive Threats: New entrants in molecular diagnostics, non-traditional point-of-care and at-home testing, safety-engineered devices, and life sciences. Disruptive technologies, including AI, and alternative therapies (e.g., oral GLP-1 medications from pharmaceutical companies) that may not require medical devices, pose additional threats.

Competitive Response Strategy: Becton, Dickinson and Company competes by emphasizing price, quality, innovation, service, reputation, distribution, and promotion. The company invests in R&D, quality management, product innovation, manufacturing, and supply chain to maintain competitiveness and boost reliability. Strategic market access initiatives, including advancing coding, coverage, and payment strategies, are critical to reducing adoption barriers and ensuring patient and provider access to medical technologies.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: Global economic conditions, including inflation, capital market volatility, interest rate and currency fluctuations, and economic slowdowns, could adversely affect demand, pricing, supply chain, and borrowing costs. Reductions in healthcare capital spending and U.S. federal funding also impact demand. Technology Disruption: Rapid technological change and scientific discoveries by competitors, including the use of emerging technologies like AI, could render Becton, Dickinson and Company's products obsolete or less competitive. Alternative therapies for diseases, potentially delivered without medical devices, also pose a risk. Customer Concentration: No single customer accounts for 10% or more of total revenues, mitigating significant customer concentration risk.

Operational & Execution Risks

Supply Chain Vulnerabilities: Reliance on sole suppliers for certain raw materials and components creates exposure to shortages, price swings, and negotiation difficulties. Disruptions from supplier shutdowns, capacity constraints, labor issues, transportation delays, inflation, geopolitical events, or regulatory actions could impact manufacturing and sales. Capacity Constraints: Interruption of manufacturing or sterilization operations (e.g., system outages, cybersecurity incidents, natural disasters, regulatory requirements) could adversely affect production, particularly where product lines or sterilization are concentrated in a few plants. Cost Volatility: Fluctuations in the cost of raw materials (e.g., oil-based resins), components, labor, duties, freight, and energy could negatively impact operating results. New climate change regulations and sustainability efforts may also increase costs. Cybersecurity Incidents: Extensive reliance on IT systems and third-party vendors, coupled with the processing of sensitive data, exposes Becton, Dickinson and Company to cyberattacks. Such incidents could lead to regulatory inquiries, litigation, increased costs, reputational damage, lost revenue, manufacturing disruptions, and patient safety concerns. The integration of AI and acquired companies further exacerbates these risks. AI Development/Deployment: The early stages of AI development and deployment present risks related to confidentiality, privacy, data protection, cybersecurity, intellectual property, legal, regulatory, reputational, ethical, operational, and technological concerns. Failure to effectively adopt and integrate AI could adversely affect competitive positioning.

Financial & Regulatory Risks

Market & Financial Risks: Becton, Dickinson and Company's ability to service its $19.181 billion in total debt and refinance existing indebtedness depends on economic, competitive, and business factors. Debt agreements contain covenants that, if violated, could accelerate repayment obligations. Regulatory & Compliance Risks: Becton, Dickinson and Company's global operations are subject to complex and increasing state, federal, and international laws across healthcare, environmental protection, anti-corruption, fraud and abuse, export control, product safety, privacy, and AI. Non-compliance can result in significant sanctions, fines, and reputational damage.

• FDA & Foreign Agencies: Products require authorization from the FDA and foreign regulatory agencies, a process that is costly and time-consuming. Post-market compliance with good manufacturing practices (GMP) and adverse event reporting is critical.
• Consent Decree: The U.S. infusion pump business (CareFusion 303, Inc.) operates under an amended consent decree with the FDA. Non-compliance could lead to manufacturing/distribution cessation, product recalls, and significant monetary damages ($15,000 per day per violation, up to $15 million per year).
• FDA Warning Letters: Becton, Dickinson and Company is addressing warning letters for its Specimen Management and Dispensing (BD Pyxis products) businesses, with a $98 million liability accrued for the latter. Failure to adequately address these could result in further regulatory actions.
• Ethylene Oxide/Sterilization: Increased regulatory scrutiny from the EPA and state agencies regarding ethylene oxide emissions (NESHAP, ID) could lead to operational suspensions, capacity limitations, increased costs, and potential litigation.
• EU Medical Device Regulation (EU MDR) & In Vitro Diagnostic Regulation (EU IVDR): Stricter requirements impose significant compliance expenditures and potential delays due to limited notified body services.
• Legal Proceedings: Becton, Dickinson and Company is a defendant in numerous product liability claims (e.g., ~6,905 hernia repair, ~2,380 implantable ports), environmental matters, and government investigations (e.g., False Claims Act). The company accrues for probable and estimable losses, but outcomes are uncertain and could exceed current accruals. Litigation related to ethylene oxide emissions in Covington, GA, resulted in a $20 million compensatory award in one trial, with a mistrial declared for the punitive phase.
• Tax Strategy: Changes in tax laws, such as the OECD Pillar Two Model Rules, could impact the effective tax rate and financial results.

Geopolitical & External Risks

Geopolitical Exposure: International operations expose Becton, Dickinson and Company to political, social, and geopolitical instability (e.g., Ukraine, Middle East, Asia), war, terrorism, and civil unrest. Trade Relations: Tariffs, sanctions, trade barriers, and export controls imposed by governments could adversely impact supply chain costs, product demand, and business operations. Natural Disasters & Public Health Crises: Unpredictable events like natural disasters, pandemics, and labor disruptions could cause economic disruption, decreased product demand, and adverse impacts on manufacturing and distribution capabilities.

Innovation & Technology Leadership

Research & Development Focus: Becton, Dickinson and Company's R&D efforts are concentrated on accelerating innovation in smart devices, robotics, analytics, and artificial intelligence to enable new care settings, improve outcomes, streamline workflows, and reduce healthcare costs. The company aims to expand category leadership and build a robust product pipeline. Core Technology Areas: Key areas include advanced monitoring solutions (BD Advanced Patient Monitoring), prefillable drug delivery systems, automated diagnostics, and fluorescence-activated cell analysis. Innovation Pipeline: Becton, Dickinson and Company invests in R&D to drive new product programs and maintain a robust pipeline. R&D Expenditure: $1.265 billion in fiscal year 2025, representing 5.8% of total revenue. R&D Facilities: R&D activities are conducted at operating units and global centers of excellence in the United States, India, China, Singapore, and Ireland, with the majority in North America.

Intellectual Property Portfolio: Becton, Dickinson and Company owns significant intellectual property, including patents, patent applications, technology, trade secrets, know-how, copyrights, and trademarks, and is licensed under others' IP. While important, no single IP asset is considered material to the business as a whole or any segment. The company faces risks from patent expirations, legal challenges, competitors designing around IP, and infringement claims.

Technology Partnerships: Becton, Dickinson and Company collaborates with universities, medical centers, and other entities on R&D programs and engages individual consultants and partners for specialized fields. The company also plans to pursue new AI technology partnerships.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Becton, Dickinson and Company emphasizes attracting and retaining key employees and executives. The company offers targeted, nomination-based programs through BD University to develop high-potential leaders and strengthen succession planning efforts.

Board Composition: The Board of Directors oversees the company's Enterprise Risk Management program, including cybersecurity risk management. The Audit Committee, composed of six independent Directors, and the Quality and Regulatory Committee (QRC) are delegated oversight of the cybersecurity risk management program.

Human Capital Strategy

Workforce Composition: As of September 30, 2025, Becton, Dickinson and Company employed approximately 72,000 associates across 61 countries. Talent Management: Acquisition & Retention: Becton, Dickinson and Company's total rewards program is designed to attract and retain top talent, incentivizing performance aligned with business strategy and values. The company invests in associates to be an employer of choice. Employee Value Proposition: The comprehensive total rewards program includes market-competitive pay, broad-based stock grants and bonuses, healthcare benefits, retirement savings plans, paid time off, family leave, flexible work schedules, on-site health and fitness centers, free physicals and flu vaccinations, well-being education and resources, and employee assistance programs. Efforts are made to mitigate rising healthcare costs and offer cost-effective benefits, particularly for associates earning $55,000 or less annually. The company is committed to fair and equitable compensation, conducting audits and benchmarking to address disparities. Diversity & Development: Becton, Dickinson and Company fosters a purpose-driven culture and inclusive work environment, believing it enhances understanding of patient and customer needs. Performance management, talent development, and internal education (BD University) are key to associate growth. The annual Strategic Organizational Planning process identifies and addresses capability gaps. Nine Associate Resource Groups (ARGs) are sponsored by executive leaders.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Becton, Dickinson and Company is investing in an enterprise-wide renewable energy strategy to enhance operational resilience. The company has proactively installed fugitive emissions controls at its facilities in East Columbus, NE, and Sandy, UT, and is implementing changes to comply with the EPA's revised NESHAP for ethylene oxide emissions, which will incur additional costs and investments in new technologies. Supply Chain Sustainability: The company collaborates across its supply chain to responsibly source materials and goods and reduce environmental impacts.

Social Impact Initiatives: Community Investment: Becton, Dickinson and Company offers volunteer opportunities for associates to support health systems in low-resource settings and provides paid time off, a matching gift program, and grants for nonprofits in honor of exceptional volunteer efforts. Product Impact: The company's purpose is "advancing the world of health," and it builds diverse teams to better understand and meet the needs of varying populations globally. Recognition: In 2025, Becton, Dickinson and Company was recognized as one of America’s Most Innovative Companies by Fortune, among the World’s Best Companies by TIME, and World’s Best Employers by Forbes. It also received the Business Group on Health “Best Employers: Excellence in Health & Well-being Award” and was named among the 100 Best Corporate Citizens by 3BL, ranking among the top three in the healthcare equipment and services industry.

Business Cyclicality & Seasonality

Demand Patterns: Becton, Dickinson and Company's worldwide sales are generally not seasonal, with exceptions for certain medical devices in the Medication Delivery Solutions business unit and flu diagnostic products in the Diagnostic Solutions business unit, which are linked to seasonal diseases like influenza. Demand for products and services can be impacted by global economic downturns, macroeconomic trends, reductions in capital spending, and changes in U.S. federal funding and healthcare delivery models. Research funding from universities and governments also influences demand for certain instruments.

Planning & Forecasting: The company's efforts to optimize inventory levels and expand manufacturing capacity imply ongoing demand forecasting and capacity planning.

Regulatory Environment & Compliance

Regulatory Framework: Becton, Dickinson and Company's global operations are subject to a complex web of state, federal, and international laws covering healthcare, environmental protection, occupational health and safety, antitrust, anti-corruption, marketing, fraud and abuse, export control, transportation, product safety and efficacy, employment, labor, privacy and data protection, customs, and artificial intelligence (AI). The U.S. Food and Drug Administration (FDA) and comparable foreign agencies extensively regulate the development, testing, manufacturing, labeling, advertising, marketing, distribution, and market surveillance of medical products. Industry-Specific Regulations: The EU Medical Device Regulation (EU MDR) and In Vitro Diagnostic Regulation (EU IVDR) impose stricter requirements for marketing and selling medical devices in the EU. The U.S. Sunshine Act and similar international laws require reporting of transfers of value to healthcare providers. Ethylene Oxide Regulation: The U.S. Environmental Protection Agency (EPA) and state agencies have increased focus on ethylene oxide use and emissions. The final NESHAP for Ethylene Oxide Emissions Standards for Sterilization Facilities became effective on April 5, 2024, and the EPA published an Interim Registration Review Decision for Ethylene Oxide (ID) on January 14, 2025, imposing new requirements and stricter occupational exposure limits.

Trade & Export Controls: Becton, Dickinson and Company is subject to U.S. and foreign laws restricting business with sanctioned countries, governments, entities, and individuals. The U.S. Department of Commerce initiated a Section 232 investigation into imports of personal protective equipment, medical consumables, and medical equipment.

Legal Proceedings:

• Consent Decree: The U.S. infusion pump business (CareFusion 303, Inc.) operates under an amended consent decree with the FDA. A December 2021 non-compliance letter and a May 2024 Form 483 Notice indicate ongoing regulatory scrutiny. Failure to comply could result in manufacturing/distribution cessation, product recalls, and daily monetary penalties.
• FDA Warning Letters: Becton, Dickinson and Company received a Warning Letter in January 2018 for its former BD Preanalytical Systems unit (now Specimen Management), with ongoing commitments. A Warning Letter was also received in November 2024 for its Dispensing quality management system (BD Pyxis products), leading to a $98 million liability accrual as of September 30, 2025.
• Product Liability: The company is defending approximately 6,905 hernia repair claims, ~2,380 implantable port claims, and other mass tort litigation involving pelvic mesh and inferior vena cava filter products.
• Environmental Litigation: Becton, Dickinson and Company is a potentially responsible party in federal Superfund and state environmental proceedings. It is also defending approximately 405 lawsuits in Georgia related to ethylene oxide emissions, with one trial resulting in a $20 million compensatory award and a mistrial declared for the punitive phase.
• Government Investigations: The Department of Justice has issued Civil Investigative Demands (CIDs) regarding potential False Claims Act violations related to FloChec/QuantaFlo devices, CareFusion's contracts with the Department of Veteran’s Affairs (including Alaris and Pyxis devices), and Genesis container products.
• SEC Investigation: Becton, Dickinson and Company settled an SEC investigation in December 2024 related to Alaris infusion pump reporting issues, paying $175 million in Q1 fiscal year 2025.
• Italian Government Medical Device Payback Legislation: The Italian Constitutional Court affirmed the constitutionality of this legislation in July 2024. Becton, Dickinson and Company settled obligations for 2015-2018 by paying 25% of invoiced amounts in Q4 fiscal year 2025.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 10.8% in 2025, 15.0% in 2024, and 7.9% in 2023.
• Geographic Tax Planning: Becton, Dickinson and Company considers all historical undistributed foreign earnings as permanently reinvested as of September 30, 2025, and does not provide deferred taxes on these earnings.
• Tax Reform Impact: The OECD Pillar Two Model Rules, imposing a 15% global minimum tax, became effective in some jurisdictions in fiscal year 2025, and Becton, Dickinson and Company is assessing their impact. The 2017 Tax Cuts and Jobs Act required capitalization and amortization of R&D expenditures for tax purposes in 2025 and 2024, increasing cash taxes paid. The One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, introduces U.S. tax law amendments, which Becton, Dickinson and Company is assessing, with no material impact in fiscal year 2025.

Insurance & Risk Transfer

Risk Management Framework: Becton, Dickinson and Company selectively uses financial instruments to manage market risks, primarily foreign currency exchange risk and interest rate risk. Insurance Coverage: The company believes some legal settlements and defense costs may be covered by applicable insurance policies or indemnification obligations. However, for certain product liability claims, Becton, Dickinson and Company has limited or no remaining insurance coverage and may not secure adequate additional protection. Risk Transfer Mechanisms: Becton, Dickinson and Company hedges substantially all transactional foreign currency exposures, primarily using forward contracts. Currency exposure for investments in foreign subsidiaries is hedged with foreign currency-denominated debt and cross-currency swaps designated as net investment hedges, as well as currency exchange contracts. Interest rate swaps are used to balance fixed and variable rate debt and manage interest rate exposures, designated as cash flow or fair value hedges.